OmniComm Systems receives EU-U.S. Privacy Shield CertificationThursday, August 31, 2017
“This is an important achievement,” said Djuro Blanuscha, OmniComm Europe GmbH’s data protection officer. “We have made great efforts to implement the high European data protection standards throughout the entire company, and we will continue to work to ensure compliance with the related regulations in the future.”
The U.S. Department of Commerce and the European Commission developed the EU-U.S. Privacy Shield and the Swiss-U.S. Privacy Shield Frameworks “to provide companies on both sides of the Atlantic with a mechanism to comply with data protection requirements when transferring personal data from the European Union and Switzerland to the United States in support of transatlantic commerce,” according to a statement from the Privacy Shield program.
The Privacy Shield has replaced the U.S.-EU Safe Harbor Program, which was invalidated in October of 2015. More information about the Privacy Shield can be found at: https://www.privacyshield.gov
“OmniComm values and respects the confidentiality and the protection of personal data. With our commitment to comply with Privacy Shield requirements, we assure our European clients and partners that their personal information is handled in adherence to the strict European data privacy principles when it is transferred to the U.S.,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 5,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. For more information, visit: www.omnicomm.com
Leiden based VarmX announces publication in Nature: approach to restore blood clotting in patients using anticoagulants inspired by snake venom
IGZ and CBG choose Biotech Training Facility for training purposes
Hercules Pharmaceuticals receives investment from UNIIQ for the development of cancer immunotherapy